Engineered SIRP alpha variants as immunotherapeutic adjuvants to anticancer antibodies.
Weiskopf, K., Ring, A.M., Ho, C.C., Volkmer, J.P., Levin, A.M., Volkmer, A.K., Ozkan, E., Fernhoff, N.B., van de Rijn, M., Weissman, I.L., Garcia, K.C.(2013) Science 341: 88-91
- PubMed: 23722425 
- DOI: 10.1126/science.1238856
- Primary Citation of Related Structures:  
4KJY - PubMed Abstract: 
CD47 is an antiphagocytic signal that cancer cells employ to inhibit macrophage-mediated destruction. Here, we modified the binding domain of human SIRPα, the receptor for CD47, for use as a CD47 antagonist. We engineered high-affinity SIRPα variants ...